Press releases

21 October, 2016

Regulatory

NeuroVive and Arbutus sign termination agreement

Lund, Sweden, October 21, 2016 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announces that the license agreement with Arbutus Biopharm ...

13 October, 2016

Regulatory

NeuroVive discontinues development of CicloMulsion for acute kidney injury

Lund, Sweden, October 13, 2016 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced results from the exploratory clinical phase II s ...

7 September, 2016

Regulatory

NeuroVive to Present at the Rodman & Renshaw 18th Annual Global Investment Conference

Lund, Sweden, September 7, 2016 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announces that the company is scheduled to present at the ...

30 August, 2016

Regulatory

NeuroVive announces that the clinical study CiPRICS will be presented at the Swedish Thorax meeting in October 2016

Lund, Sweden, August 30, 2016 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announces that the clinical study CiPRICS will be presented ...

24 August, 2016

Regulatory

NeuroVive’s Chief Operating Officer Jan Nilsson leaves the company

Lund, Sweden, August 24, 2016 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announces that its Chief Operating Officer, Jan Nilsson lea ...

9 August, 2016

Regulatory

NeuroVive’s novel strategy for treatment of mitochondrial disease published in Nature Communications

Lund, Sweden, August 9, 2016 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announces that research results from the NVP015 program inve ...

6 July, 2016

Regulatory

NeuroVive announces Arbutus Biopharma’s notice of termination

Lund, Sweden, July 6, 2016 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announces that Arbutus Biopharma (formerly OnCore Biopharma, I ...

7 June, 2016

Regulatory

NeuroVive announces CiPRICS study completes enrolment

Lund, Sweden, 7 June 2016 - NeuroVive Pharmaceutical AB (publ), announces that the CiPRICS (Ciclosporin to Protect Renal function In Cardiac Surgery) clinical research team at the Department of Cardio ...

29 April, 2016

Regulatory

NeuroVive Pharmaceutical AB (publ): Report from AGM

NeuroVive Pharmaceutical AB (publ) held its Annual General Meeting (AGM) yesterday, 28 April 2016. A summary of the resolutions follows. All resolutions were passed with the required majority.

28 April, 2016

Regulatory

NeuroVive’s R&D Team to Present Research Progress at Mitochondrial Medicine Conference

NeuroVive Pharmaceutical AB (publ), the pioneers in mitochondrial medicine, will present important research findings together with researchers at Lund University in three scientific poster presentatio ...

26 April, 2016

Regulatory

NeuroVive insiders and employees intend to subscribe for a minimum of 5.4 million SEK

NeuroVive Pharmaceutical AB (publ) announces that board members, other insiders and employees intend to subscribe for a minimum of 129 000 units, equivalent to at least SEK 5.4 million, in the company ...

26 April, 2016

Regulatory

NeuroVive starts preclinical TBI program in collaboration with PENN

NeuroVive Pharmaceutical AB (publ), the pioneers in mitochondrial medicine, announces the start of the first study in the preclinical program in traumatic brain injury (TBI) which is being done in col ...